Oncology
Prostate Cancer Value Starts Counting Cognition
ARACOG data presented at ASCO showed less cognitive decline with darolutamide than enzalutamide, bringing memory, attention and daily function into the prostate cancer treatment-value debate.
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Lung Cancer Screening Now Has a Diagnostic Bottleneck
Liquid Biopsy Turns Precision Oncology Into an NHS Delivery Test
Molecular Testing Is Europe’s Real Precision Oncology Infrastructure
Cancer Approval Is No Longer Enough
Europe’s Cancer Inequality Map Becomes a Performance Test
Europe’s Cancer Projects Start Looking Like Delivery Infrastructure
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.